Brett Staahl

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵

We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation @BStaahl. Details below & more to come at @ASGCTherapy later this week! 🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability 🕒 May 11 at 3:07 pm ET

Happy #DNADay26! Today, we celebrate the ongoing innovations in genetics and epigenetics that are shaping the future of human health. 🧬 At Scribe, we're committed to bringing novel #CRISPR-based genetic medicines to patients in need. Learn more at scribetx.com.

Interested in a deeper dive into the science and engineering behind STX-1150 and our ELXR epigenetic silencing tech? Check out @BioWorld’s feature on the scientific highlights for in vivo genetic medicine in 2025. bioworld.com/articles/72745…

Hypercholesterolemia is a major driver of cardiovascular disease. This @BioWorld article covers our work to advance STX-1150 – designed to durably lower LDL-C via epigenetic silencing of PCSK9 – into the clinic and meaningfully change how #CVD is treated. bioworld.com/articles/72818…

At Scribe, we believe the standard of cardiovascular care today needs a paradigm shift. @CardioBusiness spotlights our development of novel #CRISPR-based medicines that target the key lipid drivers of ASCVD – check out the article preview and link below. 👇

Our thanks to @BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer. The result: Improved precision for CRISPR-based therapeutics. Details⬇️

Read more about our approach to improving cardiovascular health and longevity in this @LongevityTech piece by @mrdannysullivan: longevity.technology/news/epigeneti… #HeartDisease #OurHearts #HeartMonth

Can #CRISPR genetic medicine solve cardiovascular disease? We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @LongevityTech article below 👇

@scribetx This Scribe Therapeutics Team has heart! Miles and miles and miles of heart!

We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️‍🩹 Join us and learn more about what you can do to protect yourself and your loved ones by visiting: nhlbi.nih.gov/health/heart-h… #HeartDisease #OurHearts #HeartMonth

This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot. 📅 September 25, 2025 🕗 3:15pm ET 📍 Virtual ✅ Register for the event or reach out to our team at scribetx.com/contact

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

📣 Presenting new breakthrough data from two of our core platforms 📣 We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics. More details in our link below 👇

At Scribe, we run on teamwork and purpose – in and out of the lab. #JPMCC 2025 marked our 4th year participating in the global @jpmorgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

Benjamin Oakes, Ph.D., Scribe Therapeutics cofounder and CEO, spoke about what the next generation of therapies looks like at the 2024 Forbes Healthcare Summit in New York City. #ForbesHealth trib.al/BnATMd9

We’re pleased to report new preclinical data on the potency, specificity, and safety of our #CRISPR XE genome editing and ELXR epigenome modifying technologies to address #CardiometabolicDisease. Read our #AHA24 highlights below and in our press release: businesswire.com/news/home/2024…

Join us next week at the 42nd Annual @jpmorgan Healthcare Conference for a presentation by our CEO @BenjaminLOakes. #JPM24 details below and in our press release: ow.ly/zI1w50QmZYo 📅 Monday, January 8, 2024 🕓 4:30pm PT

From our science to our potlucks, we’re thankful to every member of the Scribe team for their contributions to our mission and community. Wishing all a restful and happy #Thanksgiving!